We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Catalent, Inc (CTLT) is a leading drug manufacturers-specialty & generic business with stocks listed in the US. It opened the day at US$108.47 after a previous close of US$108.47. During the day the price has varied from a low of USD107.815 to a high of USD109.33. The latest price was USD108.83 (25 minute delay). Catalent is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in Catalent
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Catalent. Find the share by name or ticker symbol: CTLT. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Catalent reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$100.61, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Catalent, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Catalent. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
Catalent share priceUse our graph to track the performance of CTLT stocks over time.
Catalent shares at a glance
|52-week range||US$69.52 - US$127.68|
|50-day moving average||US$105.0824|
|200-day moving average||US$107.6273|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$2.953|
Compare share trading platforms to buy stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Catalent stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Catalent price performance over time
|1 week (2021-06-17)||-1.56%|
|1 month (2021-05-24)||6.11%|
|3 months (2021-03-23)||1.33%|
|6 months (2020-12-23)||3.79%|
|1 year (2020-06-23)||52.49%|
|2 years (2019-06-21)||104.41%|
|3 years (2018-06-22)||161.99%|
|5 years (2016-06-23)||359.97%|
Is Catalent under- or over-valued?
Valuing Catalent stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalent's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Catalent's P/E ratio
Catalent's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, Catalent shares trade at around 37x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Catalent's PEG ratio
Catalent's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.2624. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Catalent's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Catalent's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$875.8 million.
The EBITDA is a measure of a Catalent's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||US$3.8 billion|
|Operating margin TTM||15.79%|
|Gross profit TTM||US$983.3 million|
|Return on assets TTM||4.68%|
|Return on equity TTM||16.22%|
|Market capitalisation||US$18.4 billion|
TTM: trailing 12 months
Shorting Catalent shares
There are currently 2.4 million Catalent shares held short by investors – that's known as Catalent's "short interest". This figure is 5.5% up from 2.3 million last month.
There are a few different ways that this level of interest in shorting Catalent shares can be evaluated.
Catalent's "short interest ratio" (SIR)
Catalent's "short interest ratio" (SIR) is the quantity of Catalent shares currently shorted divided by the average quantity of Catalent shares traded daily (recently around 1.1 million). Catalent's SIR currently stands at 2.13. In other words for every 100,000 Catalent shares traded daily on the market, roughly 2130 shares are currently held short.
However Catalent's short interest can also be evaluated against the total number of Catalent shares, or, against the total number of tradable Catalent shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catalent's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Catalent shares in existence, roughly 10 shares are currently held short) or 0.0141% of the tradable shares (for every 100,000 tradable Catalent shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Catalent.
Find out more about how you can short Catalent stock.
Catalent share dividends
We're not expecting Catalent to pay a dividend over the next 12 months.
Catalent share price volatility
Over the last 12 months, Catalent's shares have ranged in value from as little as US$69.52 up to US$127.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Catalent's is 1.4505. This would suggest that Catalent's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Frequently asked questions
More guides on Finder
Prime Day deal: $100 off Sony’s ‘Bose Killing’ Headphones
Get 33% off Sony WH1000XM3 Wireless Noise Cancelling Headphones during Amazon Prime Day 2021. Here's how to get the deal before it disappears.
Amazon Prime Day best book deals for all ages: Up to 55% off
Snap up best-selling reads for the whole family with these great Australian Prime Day offers.
The best Amazon Prime Day phone deals Australia: $600 off
Top offers include 57% off phone accessories, 38% off OPPO and 36% off Nokia.
Amazon Prime Day’s best appliance deals: 49% off De’Longhi, Philips
From air fryers to coffee makers to vacuum cleaners and more, these are the very best appliance deals that Amazon has to offer this Prime Day.
Amazon Prime Day: 75% off these massive beauty brands
Prime Day is your only chance to save big on Olaplex, Maybelline, La-Roche Posay, Calvin Klein fragrances and more.
Best Amazon Prime Day headphone deals: 58% off Sony + heaps more
Top headphone offers include 58% off Sony, 54% off Sennheiser and 45% off Bose.
Prime Day 2021: Up to 40% off tablets from Lenovo, Samsung and Huawei
Prime Day is here – don't miss your chance to save big on these tablets from your favourite tech brands.
Finder Daily Deals: The 5 best deals in Australia today
Today's best Finder Daily deals include: Amazon Prime Day 2021 deals, $270 off Sunbeam coffee machines, $70 off Xbox Series S.
The best Amazon Prime Day deals from Aussie brands: Get 45% off
Here are the Prime Day deals you can feel especially good about shopping.
Amazon Prime Day Australia 2021: All the best deals from Day 2
Here are all the best deals from Amazon Prime Day Australia's second day - including the return of dirt-cheap Nintendo Switch consoles.
Ask an Expert